# Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

> **NCT04335071** · PHASE2 · TERMINATED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 5 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Tocilizumab (TCZ)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04335071
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-26
- **Primary completion:** 2020-09-27
- **Final completion:** 2020-09-27
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** 1.) Not possible to recruit the planned number of patients during the planned study period; 2.) "Dexamethason" was included in the standard of care for the study population during the course of the study and inclusion criteria could no longer be met.
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335071, "Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04335071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*